other material
confidence high
sentiment positive
materiality 0.75
Viridian Therapeutics licenses veligrotug, VRDN-003 to Kissei for Japan; $70M upfront, up to $315M milestones
Viridian Therapeutics, Inc.\DE
- Upfront payment of $70M; up to $315M in development, regulatory, and commercial milestones.
- Tiered royalties on Japan net sales in the 20s to mid-30s percent range.
- Kissei gets exclusive Japan rights; Viridian retains manufacturing/supply responsibilities except limited cases.
- Veligrotug (VRDN-001) and VRDN-003 are anti-IGF-1R antibodies targeting thyroid eye disease.
- THRIVE and THRIVE-2 phase 3 trials for veligrotug met all primary and secondary endpoints.